Treatment of phantom pain with botulinum-toxin A. A pilot study;Botulinum-Toxin-A in der behandlung von phantomschmerzen eine pilotstudie

Schmerz

Volumn 17, Issue 2, 2003, Pages 117-124

  Kern, U ^a   Martin, C ^a   Scheicher, S ^a   Muller H ^a  

^a Stadtisches Klinikum Kemperhof   (Germany)

Author keywords

Amputees; Botulinum toxin; Phantom pain; Postamputation pain; Triggerpoint

Indexed keywords

BOTULINUM TOXIN A; NEUROTRANSMITTER; SUBSTANCE P; MUSCLE RELAXANT AGENT;

ADULT; AMPUTATION; ARTICLE; CASE REPORT; CENTRAL NERVOUS SYSTEM; CHRONIC PAIN; CONTROLLED STUDY; HUMAN; MUSCLE WEAKNESS; NEUROMODULATION; NOCICEPTION; PAIN ASSESSMENT; PHANTOM PAIN; PILOT STUDY; SLEEP DISORDER; TREATMENT OUTCOME; VISUAL ANALOG SCALE; AGED; AGNOSIA; FEMALE; MALE; MIDDLE AGED;

ADULT; AGED; BOTULINUM TOXIN TYPE A; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; PHANTOM LIMB; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 0038206531     PISSN: 0932433X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00482-003-0202-5     Document Type: Article

References (111)

1. Adler T (2001) Nachweis kortikaler Reorganisation bei Patienten mit Armamputationen und die Beziehung zu Phantomschmerzen - eine fMRT-Studie. Z Orthop Ihre Grenzgeb 139(2):M29-30
2. Alam M, Dover JS, Arndt KA (2002) Pain associated with injection of botulinum A exotoxin reconstituted using isotonic sodium chloride with and without preservative: a double-blind, randomized controlled trial. Arch Dermatol 138(4):510-514
3. Andre JM, Martinet N, Paysant J, Beis JM, Le Chapelain L (2001) Temporary phantom limbs evoked by vestibular caloric stimulation in amputees. Neuropsychiatry Neuropsychol Behav Neurol 14(3):190-196
4. Aoki R (1998) The development of BOTOX - its history and pharmacology. Pain Digest 8:337-341
5. Aoki KR, Guyer B (2001) Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol 8 [suppl 5]:21-29
6. Aoki KR (2001) Pharmacology and immunology of botulinum toxin serotypes. J Neurol 248 [suppl 1]:3-10
7. Baron R, Wasner G, Lindner V (1998) Optimal treatment of phantom limb pain in the elderly. Drugs Aging 12(5):361-376
8. Belleggia G, Birbaumer N (2001) Treatment of phantom limb pain with combined EMG and thermal biofeedback: a case report. Appl Psychophysiol Biofeedback 26(2):141-146
9. Binder WJ, Brin MF, Blitzer A, Schoenrock LD, Pogoda JM (2000) Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg 123(6):669-676
10. Bone M, Critchley P, Buggy DJ (2002) Gabapentin in postamputation phantom limb pain: a randomized, double-blind, placebo-controlled, cross-over study. Reg Anesth Pain Med 27(5):481-486
11. Boyd RN, Graham HK (1999) Objective measurement of clinical findings in the use of botulinum toxin type A for the management of children with cerebral palsy. Eur J Neurol 6 [suppl 4]:S23-S35
12. Brin MF, Fahn S, Moskowitz C et al. (1987) Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord 2(4):237-254
13. Brückner L (2001) Der Wert des aktiven Sauerbruch-Armes und seine positive Auswirkung aufden Phantomschmerz. Med Orth Tech 121:3-10
14. Canavero S, Bonicalzi V, Castellano G, Perozzo P, Massa-Micon B (1999) Painful supernumerary phantom arm following motor cortex stimulation for central poststroke pain. Case report. J Neurosurg 91(1):121-123
15. Carvatho GA, Nikkhah G, Samii M (1997) Pain management after post-traumatic brachial plexus lesions. Conservative and surgical therapy possibilities. Orthopade 26(7):621-625
16. Ceballos-Baumann AO, Sheean G, Passingham RE, Marsden CD, Brooks DJ (1997) Botulinum toxin does not reverse the cortical dysfunction associated with writer's cramp. A PET study. Brain 120:571-582
17. Childers MK, Kornegay JN, Aoki R, Otaviani L, Bogan DJ, Petroski G (1998) Evaluating motor end-plate-targeted injections of botulinum toxin type A in a canine model. Muscle Nerve 21(5):653-655
18. Cui M, Aoki KR (2000) Botulinum-toxin A (BTX-a) reduces inflammatory pain in the rat formalin model. Cephalalgia 20:414
19. Dertwinkel R, Strumpf M, Zenz M (1998) Sympathische Reflexdystrophie und Phantomschmerz. Diagnose, Therapie und Prognose. Z Arztl Fortbild Qualitatssich 92(1):35-40
20. Diemath H (1969) Rehabilitation der Amputierten (Aussprache). Hefte zur Unfallheilkunde 100:133
21. Dolly JO (1994) In: Poewe W (Hrsg) Neue Perspektiven für die Therapie mit Botulinum Toxin A. Wissenschaftsverlag Wellingsbüttel, Hamburg, S 42
22. Dunne JW, Heye N, Dunne SL (1995) Treatment of chronic limb spasticity with botulinum toxin A.J Neurol Neurosurg Psychiatry 58(2):232-235
23. Filippi GM, Errico P, Santarelti R, Bagolini B, Manni E (1993) Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol 113(3):400-404
24. Flor H, Elbert T, Knecht S (1995) Phantom-limb pain as a perceptual correlate of cortical reorganisation following arm amputation. Nature 375:482-484
25. Flor H, Elbert T, Muhlnickel W, Pantev C,Wienbruch C, Taub E (1998) Cortical reorganization and phantom phenomena in congenital and traumatic upper-extremity amputees. Exp Brain Res 119(2):205-212
26. Flor H (1999) Helping patients with phantom pain. Prosthesis for the brain? Interview by Dipl. Biochem. Petra Eiden. MMW Fortschr Med 141(51-52):16
27. Foster L. Clapp L, Erickson M,Jabbari B (2001) Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology 22;56(10):1290-1293
28. Franke F (1975) Arterielle occlusion in two leg amputees: "phantom claudication" due to pelvic-artery stenosis. Dtsch Med Wochenschr 100(44):2275-2277
29. Fraser CM, Halligan PW, Robertson IH, Kirker SG (2001) Characterising phantom limb phenomena in upper limb amputees. Prosthet Orthot Int 25(3):235-242
30. Freund B, Schwartz M, Symington JM (2000) Botulinum toxin: new treatment for temporomandibular disorders. Br J Oral Maxillofac Surg 38(5):466-471
31. Giladi N (1997) The mechanism of action of botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injected site.J Neurol Sci 152(2):132-135
32. Gilio F, Curra A, Lorenzano C, Modugno N, Manfredi M, Berardelli A (2000) Effects of botulinum toxin type A on intracortical inhibition in patients with dystonia. Ann Neurol 48(1):20-26
33. Glocker FX, Guschlbauer B, Lucking CH, Deuschl G (1995) Effects of local injections of botulinum toxin on electrophysiological parameters in patients with hemifacial spasm: role of synaptic activity and size of motor units. Neurosci Lett 187(3):161-164
34. Glockner FX (1995) Wirkmechanismen von Botulinumtoxin bei der Behandlung von Hyperkinesien. In: Deuschl G (Hrsg) Botulinumtoxin-Forum 1995.Wissenschaftverlag Wellingsbüttel, Hamburg, S 31-36
35. Göbel H, Heinze A, Heinze-Kuhn K, Jost WH (2001) Evidence-based medicine: botulinum toxin A in migraine and tension-type headache. J Neurol 248 [suppl 1]:34-38
36. Göbel H,Heinze A, Heinze-Kuhn K, Austermann K (2001) Botulinum-Toxin Ain der Therapie von Kopfschmerzerkrankungen und perikraniellen Syndromen, Nervenarzt 72:261-274
37. Gross D (1981) Contralateral local anesthesia in the treatment ofstump and phantom pain. Munch Med Wochenschr 123(36):1332
38. Gross D (1984) Contralateral local anesthesia in stump, phantom and post-traumatic pain. Reg Anaesth 7(2):65-73
39. Guyer B (1999) Botulinum toxin type A: new therapeutic directions. Eur J Neurol 6:S121-123
40. Hess CW, Mills KR, Murray NM (1986) Magnetic stimulation of the human brain: facilitation of motor responses by voluntary contraction of ipsilateral and contralateral muscles with additional observations on an amputee. Neurosci Lett 71(2):235-240
41. Hesse S, Krajnik J, Luecke D, Jahnke MT, Gregoric M, Mauritz KH (1998) Ankle muscle activity before and after botulinum toxin therapy for lower limb extensor spasticity in chronic hemiparetic patients. Stroke 27(3):455-460
42. Hesse S, Reiter F, Konrad M,Jahnke MT (1998) Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double-blind, placebo-controlled trial. Clin Rehabil 12(5):381-388
43. Hill A (1999) Phantom limb pain: a review of the literature on attributes and potential mechanisms. J Pain Symptom Manage 17(2):125-142
44. Humm AM, Pabst C, Lauterburg T, Burgunder JM (2000) Enkephalin and aFGF are differentially regulated in rat spinal motoneurons after chemodenervation with botulinum toxin. Exp Neurol 161(1):361-372
45. Huse E, Larbig W, Birbaumer N, Flor H (2001) Kortikale Reorganisation und Schmerz Empirische Befunde und therapeutische Implikationen am Beispiet des Phantomschmerzes. Schmerz 15(2):131-137
46. Ishikawa H, Mitsui Y, Yoshitomi T, Mashimo K, Aoki S., Mukuno K, Shimizu K (2000) Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilatator muscles. Jpn J Ophthalmol 44(2):106-109
47. Jaeger H, Maier C,Wawersik J (1988) Postoperative treatment of phantom pain and causalgias with calcitonin. Anaesthesist 37(2):71-76
48. Jaeger H, Maier C (1992) Calcitonin in phantom limb pain: a double-blind study. Pain 48(1):21-27
49. Jost WH (1997) One hundred cases of anal fissure treated with botulin toxin: early and long-term results. Dis Colon Rectum 40(9):1029-1032
50. Kanovsky P, Streitova H, Dufek J, Znojil V, Daniel P, Rektor I (1998) Change in lateralization of the P22/N30 cortical component of median nerve somatosensory evoked potentials in patients with cervical dystonia after successful treatment with botulinum toxin A. Mov Disord 13(1):108-117
51. Katz J (1992) Psychophysical correlates of phantom limb experience. J Neurol Neurosurg Psychiatry 55(9):811-821
52. Kelm S, Gerats G, Chalkiadaki A, Hefter H (2001) Reduction of pain and muscle spasms by botulinum toxin A. Nervenarzt 72(4):302-306
53. Kew JJ, Ridding MC, Rothwell JC, Passingham RE, Leigh PN, Sooriakumaran S, Frackowiak RS, Brooks DJ (1994) Reorganization of cortical blood flow and transcranial magnetic stimulation maps in human subjects after upper limb amputation. J Neurophysiol 72(5):2517-2524
54. Kim KS, Kim SS,Yoon JH, Han JW (1998) The effect of botulinum toxin type A injection for intrinsic rhinitis. J Laryngol Otol 112(3):248-251
55. Knecht S,Ringelstein EB (1999) Neuronale Plastizität am Beispiel des somatosensorischen Systems. Nervenarzt 70(10):889-898
56. Konrad H, Karamfilov T (2000) Botulinum toxin A Therapie bei Stumpfdermatitis durch fokale Hyperhidrosis. Z Hautkr 75/6:390
57. Kooijman CM, Dijkstra PU, Geertzen JH, Elzinga A, van der Schans CP (2000) Phantom pain and phantom sensations in upper limb amputees: an epidemiological study. Pain 87(1):33-41
58. Kristen H, Lukeschitsch G, Plattner F, Sigmund R, Resch P (1984) Thermography as a means for quantitative assessment of stump and phantom pains. Prosthet Orthot Int 8(2):76-81
59. Laskawi R (2002) 1st British-German botulinum toxin forum, London, Dez 2002, persönliche Mitteilung
60. Melzack R, Loeser JD (1978) Phantom body pain in paraplegics: evidence for a central "pattern generating mechanism" for pain. Pain 4(3):195-210
61. Melzack R, Wall PD (1988) The challenge of pain, 2nd ed. Penguin Books,London
62. Melzack R (1990) Phantom limbs and the concept of a neuromatrix. Trends Neurosci 13(3):88-92
63. Mense 5 (1999) Neurobiotogische Grundlagen von Muskelschmerz. 5chmerz 13:3-17
64. Meyer M (1994) Dystonien des Gesichtes und Halses. In: Poewe W (Hrsg) Neue Perspektiven für die Therapie mit Botulinum Toxin A.Wissenschaftsverlag Wellingsbüttel, Hamburg, 5 79-88
65. Moreno-Lopez B, de la Cruz RR, Pastor AM, Delgado-Garcia JM (1994) Botulinum neurotoxin alters the discharge characteristics of abducens motoneurons in the alert cat. J Neurophysiol 72(4):2041-2044
66. Moreno-Lopez B, Pastor AM, de la Cruz RR, Delgado-Garcia JM (1997) Dose-dependent, central effects of botulinum neurotoxin type A: a pilot study in the alert behaving cat. Neurology 48(2):456-464
67. Murray M, Goldberger ME (1986) Replacement of synaptic terminals in lamina II and Clarke's nucleus after unilateral lumbosacral dorsal rhizotomy in adult cats. J Neurosci 6(11):3205-3217
68. Naumann M (2001) Evidence-based medicine: botulinum toxin in focal hyperhidrosis. J Neurol 248 [suppl 1]:31-33
69. Naumann MK, Lowe NJ (2002) Effect of botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial. Br J Dermatol 147(6):1218-1226
70. Nikolajsen L, Ilkjaer S, Jensen TS (2000) Relationship between mechanical sensitivity and postamputation pain: a prospective study. Eur J Pain 4(4):327-334
71. Nikolajsen L, Lindvig M (2001) Phantom pain after amputation of extremities. Ugeskr Laeger 163(24):3338-3341
72. Pierson SH, Katz DI, Tarsy D (1996) Botulinum toxin A in the treatment of spasticity: functional implications and patient selection. Arch Phys Med Rehabil 77(7):717-721
73. Polo KB, Jabbari B (1994) Botulinum toxin-A improves the rigidity of progressive supranuclear palsy. Ann Neurol 35(2):237-239
74. Porta M (1999) Botulinum toxin type A injections for myofascial pain syndrome and tension-type headache. Eur J Neurol 6:S103-109
75. Purkiss J,Welch M, Doward S, Foster K (2000) Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement oftwo distinct mechanisms. Biochem Pharmacol 59(11):1403-1406
76. Racz GB (1998) Botulinum-toxin as a new approach for refractory pain syndromes. Pain Digest Vigest 8:353-356
77. Rambert S (1989) Phantom pain. Ther Umsch 46(8):555-560
78. Rand MJ, Whaler BC (1965) Impairment of sympathetic transmission by botulinum toxin. Nature 206(984):588-591
79. Relchel G (2001) Botulinum toxin for treatment of spasticity in adults. J Neurol 248 [suppl 1]:25-27
80. Reichert K, Sewekow K (2002) A man with 3 arms. Phantom limb perception in intramedullary ependymoma, Nervenarzt 73(6):548-551
81. Relja MA (1997) Treatment of tension-type headache by local injection of botulinum toxin. Eur J Neurol 4 [suppl 2]:71-73
82. Richardson D, Sheean G, Werring D, Desai M, Edwards S, Greenwood R (2000) Evaluating the role of botulinum toxin in the management of focal hypertonia in adults. J Neurol Neurosurg Psychiatry 69(4):499-506
83. Rosales RL, Arimura K, Takenaga S, Osame M (1996) Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve 19(4):488-496
84. Sala C, Andreose JS, Fumagatli G, Lomo T (1995) Calcitonin gene-related peptide: possible role in formation and maintenance of neuromuscular junctions. J Neurosci 15:520-528
85. Schmid HJ (2000) Phantom limb after amputation-overview and new knowledge. Schweiz Rundsch Med Prax 89(3):87-94
86. Shaari CM, Sanders I, Wu BL, Biller HF (1995) Rhinorrhea is decreased in dogs after nasal application of botulinum toxin. Otolaryngol Head Neck Surg 112(4):566-571
87. Sharma MC, TeIla P, Wu CL (2002) Phantom and postamputation pain. Int J Pain Med Palliat Care 1(3):82-89
88. Sherman RA, Bruno GM (1987) Concurrent variation of burning phantom limb and stump pain with near surface blood flow in the stump. Orthopedics 10(10):1395-1402
89. Sherman RA, Griffin VD, Evans CB, Grana AS (1992) Temporal relationships between changes in phantom limb pain intensity and changes in surface electromyogram of the residual limb. Int J Psychophysiol 13(1):71-77
90. Silberstein S, Mathew N, Saper J, Jenkins S (2000) Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache 40(6):445-450
91. Simanski C, Bathis H, Bouillon B, Koch-Epping G, Tiling T(2001) Therapiekonzept zur Verhinderung der Phantomschmerzchronifizierung nach traumatischer Armplexusläsion. Unfallchirurg 104(7):659-664
92. Simons DG (1997)Triggerpunkte und Myogelose. Manuelle Med 35:290
93. Simons DG (2001) Clinical and etiological update of myofascial pain from trigger points. J Musculoskel Pain 4:93
94. Simpson LL (1981) The origin, structure, and pharmacological activity ofbotulinum toxin. Pharmacol Rev 33(3):155-188
95. Sturm V, Kroger M, Penzholz H (1975) Problems of peripheral nerve surgery in amputation stump pain and phantom limbs. Chirurg 46(9):389-391
96. Swartling C, Naver H, Lindberg M (2001) Botulinum A toxin improves life quality in severe primary focal hyperhidrosis. Eur J Neurol 8(3):247-252
97. Travell JG, Simons DG (1998) Handbuch der Muskel-Triggerpunkte. Obere Extremität, Kopf und Thorax, Bd 1. Urban & Fischer, Lübeck Stuttgart Jena Ulm
98. Verderio C, Coco S, Rossetto O, Montecucco C, Matteoli M (1999) Internalization and proteolytic action of botulinum toxins in CNS neurons and astrocytes. J Neurochem 73(1):372-379
99. Wall PD (1981) On the origin of pain associated with amputation. In: Zimmermann SJ (ed) Phantom and stump pain. Springer, Berlin Heidelberg NewYork
100. Weiss T, Miltner WH, Adler T, Bruckner L, Taub E (1999) Decrease in phantom limb pain associated with prosthesis-induced increased use of an amputation stump in humans. Neurosci Lett 272(2):131-134
101. Welch MJ, Purkiss JR, Foster KA (2000) Sensitivity of embryonic rat dorsal root ganglia neurons to clostridium botulinum neurotoxins. Toxicon 38(2):245-258
102. Wells C (2002) Rationale for use of botulinum toxin type A in pain therapy. In: Raj P (ed) Botulium toxin type Ain pain management. Wissenschaftsverlag Wellingsbüttel, Hamburg, S 13-20
103. Wheeler AH, Goolkasian P, Gretz SS (1998) A randomized, double-blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome. Spine 23(15):1662-1666
104. Wiegand H, Erdmann G, Wellhoner HH (1976) 125-labelled botulinum A neurotoxin: pharmacokinetics in cats after intramuscular injection. Naunyn Schmiedebergs Arch Pharmacol 292(2):161-165
105. Wiegand H, Wellhoner HH (1977) The action of botulinum A neurotoxin on the inhibition by antidromic stimulation of the lumbar monosynaptic reflex. Naunyn Schmiedebergs Arch Pharmacol 298(3):235-238
106. Wiegand H, Winkelmuller W (1985) Treatment of deafferentation pain by high-frequency intervention on the dorsal root entry zone. Dtsch Med Wochenschr 110(6):216-220
107. Wissel J, Muller J, Dressnandt J, Heinen F, Naumann M,Topka H, Poewe W (2000) Management of spasticity associated pain with botulinum toxin A.J Pain Symptom Manage 20(1):44-49
108. Wollina U, Konrad H, GraefeT, Thiele J (2000) Botulinum toxin A for focal hyperhidrosis in leg amputees: a case report. Acta Derm Venereol 80(3):226-227
109. Wollina U (2000) Botulinum Toxin - Neue Einblicke zur Wirkung und dermatologischen Indikationen. Akt Dermatol 26/8-9:295-297
110. Worz R, Worz E (1990) Pain syndromes following amputation. Analysis of 100 affected patients with chronic stump and phantom pain. Fortschr Med 108(4):53-56
111. Woolf CJ, Thompson SW (1991)The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states. Pain 44(3):293-299